Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2005
10/20/2005US20050233328 Methods of identifying compounds that modulate protein activity
10/20/2005US20050233003 Nanosized particles of salicylic acid wrapped in an amphiphilic polymer of polyacrylic acid, polyacrylamide, polymethacrylamide and polylysine; polymer is modified with urea, nicotinamide or guanidine
10/20/2005US20050232950 Viruses comprising mutant ion channel protein
10/20/2005US20050232947 Bacterial spores
10/20/2005US20050232942 Virulence genes, proteins, and their use
10/20/2005US20050232933 CMV-IE1 peptides and method of use
10/20/2005US20050232907 Use of herpes vectors for tumor therapy
10/20/2005US20050232905 Use of peripheral blood cells for cardiac regeneration
10/20/2005US20050232900 Recombinant replication-defective adenovirus serotypes 11, 25, 34, 35, 48 and 49 as gene delivery vehicles for gene therapy; reduced drug resistance, increased effectiveness of vaccination
10/20/2005US20050232872 Compositions and methods for enhancing receptor-mediated cellular internalization
10/20/2005CA2590604A1 Microrna encoded by ebv, kshv and hcmv and microrna for targeting the same
10/20/2005CA2561947A1 Preventives/remedies for cancer
10/20/2005CA2561593A1 Antiobesity drug
10/20/2005CA2561221A1 Rna interference modulators of hedgehog signaling and uses thereof
10/20/2005CA2555390A1 Immunostimulatory viral rna oligonucleotides
10/19/2005EP1586655A2 Improved methods for transfecting T cells
10/19/2005EP1586654A1 Replication competent viruses capable of silencing virus inhibitory factor expression
10/19/2005EP1586646A2 Lawsonia intracellularis vaccine
10/19/2005EP1586644A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour development and for wound healing
10/19/2005EP1586642A2 Tumor supressor genes, proteins encoded thereby and use of said genes and proteins
10/19/2005EP1586582A1 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
10/19/2005EP1586581A2 Non-Mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
10/19/2005EP1586326A1 Pharmaceutical compositions for treating neuronal damage and neurodegenerative diseases
10/19/2005EP1585812A2 Multi-antigenic alphavirus replicon particles and methods
10/19/2005EP1585560A2 Delivery of molecules and complexes to mammalian cells in vivo
10/19/2005EP1585545A2 Methods of inducing and maintaining immune tolerance
10/19/2005EP1585535A2 Pthrp-derived modulators of smooth muscle proliferation
10/19/2005EP1354054B1 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses
10/19/2005EP1346045B1 Human protooncogene and protein encoded therein
10/19/2005EP1292340B1 Transfection system
10/19/2005EP1259251B1 Novel method for down-regulation of amyloid
10/19/2005EP1173217B1 Enhanced delivery of nucleic acid-based drugs
10/19/2005EP1109570B1 Modulation of memory effector t-cells with a cd2 binding agent
10/19/2005EP1104482B1 Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
10/19/2005EP1084278B1 Detection of dna, rna and proteins
10/19/2005EP1015583B1 Protein containing an srcr domain
10/19/2005EP1007631B1 Cardiac muscle regeneration using mesenchymal stem cells
10/19/2005EP1000163B1 Pseudomonas exotoxin a-like chimeric immunogens
10/19/2005EP0846173B1 Use of an anti-interleukin-9 antibody for the preparation of a medicament for the treatment of asthma
10/19/2005EP0768894B1 Multi-stage cascade boosting vaccine
10/19/2005CN1685063A Methods and compositions relating to gene silencing
10/19/2005CN1684977A Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
10/19/2005CN1683532A GATA-2 mutator as one of leukemia rapid change major genes and its use
10/19/2005CN1683405A Clonorichis sinensis II 14-3-3 protein, its coded nucleic acid and its use
10/19/2005CN1683404A Clonorichis sinensis ubiquitin homogenetic protein, its coded nucleic acid and its use
10/19/2005CN1683403A Japanese blood fluke cell periodic static agent, its coded nucleic acid and its use
10/19/2005CN1683402A Clonorichis sinensis annexin, its coded nucleic acid and its use
10/19/2005CN1683401A Clonorchis sinensis GTP bindin alpha subunit, its coded nucleic acid and its use
10/19/2005CN1683018A Gene engineering vaccine for weaning pigling diarrhea and pig hydrops disease
10/19/2005CN1683017A Heating induction method for local expression of anti-inflammation gene
10/19/2005CN1683014A Process for preparig dentritic poly lysine derivative carrier for gene therapy
10/19/2005CN1223608C Caspase-8 interacting proteins
10/18/2005US6956146 FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor
10/18/2005US6956110 Genes involved in the molecular paths of tumor suppression and/or resistance to viruses
10/18/2005US6955919 Lentiviral packaging cells and uses therefor
10/18/2005US6955905 PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use
10/18/2005US6955898 Targeting pharmaceutical agents to injured tissues
10/18/2005US6955897 Number of accessory gland proteins from Drosophila. The invention also provides an accessory gland protein which is toxic to insect cells and can be used to kill or inhibit the development of insects. Methods of controlling insects are
10/18/2005US6955894 cytokines; for increasing/decreasing signal transduction; metalloproteases; for treating inflammation during treatment of septic shock, arthritis, and/or multiple sclerosis
10/18/2005US6955883 Life sciences business systems and methods
10/18/2005US6955811 Methods of inhibiting immune response suppression by administering antibodies to OX-2
10/18/2005US6955808 Capsid-modified recombinant adenovirus and methods of use
10/18/2005US6955802 Homeodomain protein code specifying progenitor cell identify and neuronal fate in the ventral neural tube
10/18/2005CA2285633C Bacterial plasmids
10/13/2005WO2005095621A1 Method of regulating gene introduction with use of artificial magnetic material and system therefor
10/13/2005WO2005095613A1 Rad51 EXPRESSION INHIBITOR, DRUG CONTAINING THE INHIBITOR AS THE ACTIVE INGREDIENT AND UTILIZATION THEREOF
10/13/2005WO2005095606A1 Therapeutic molecules for modulating stability of vegf transcripts
10/13/2005WO2005095604A1 Rf rp transgenic animal
10/13/2005WO2005095598A1 Cancer antigen peptide originating in wt1
10/13/2005WO2005094900A1 Preventive and/or remedy for cancer
10/13/2005WO2005094899A1 Clusterin antisense therapy for treatment of cancer
10/13/2005WO2005094887A1 sFRP EXPRESSION POTENTIATING AGENT
10/13/2005WO2005094876A1 Diagnostics and therapeutics for diseases associated with p21 (cdkn1a)-activated kinase 2 (pak2)
10/13/2005WO2005094866A1 Adiponectin expression inducer and utilization of the same
10/13/2005WO2005094846A1 Remedy for prion disease and method of producing the same
10/13/2005WO2005094587A1 Genetically modified heart valve xenografts
10/13/2005WO2005094420A2 Materials and methods for treatment of inflammatory and cell proliferation disorders
10/13/2005WO2005094415A2 Recombinant vectors and methods for inducing an immune response
10/13/2005WO2005094370A2 Oligonucleotide complex compositions and methods of use as gene alteration tools
10/13/2005WO2005082415A3 Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
10/13/2005WO2005070011A3 Improved modalities for the treatment of degenerative diseases of the retina
10/13/2005WO2005058352A3 Treatment of rheumatoid arthritis with galectin-3 antagonists
10/13/2005WO2005056749A3 Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
10/13/2005WO2005038035A3 Methods for producing and using in vivo pseudotyped retroviruses
10/13/2005WO2005028658A9 Recombinant influenza vectors with a polii promoter and ribozymes
10/13/2005WO2005001055A3 Stabilized immunomodulatory oligonucleotides
10/13/2005WO2004090107A3 Endosomolytic polymers
10/13/2005WO2004074509A3 Reversible attachment of a membrane active polymer to a polynucleotide
10/13/2005WO2004072253A3 Human excitatory amino acid transporter-2 gene promoter and uses thereof
10/13/2005WO2003078576A3 Vector for transfection of eukaryotic cells
10/13/2005WO2003068954A8 Microorganism for genetic therapeutic treatment of proliferative diseases
10/13/2005US20050229272 Compositions and methods for gene silencing
10/13/2005US20050229264 Recombinant gelatins
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050227940 Amplifying interfering RNA (RNAi) expression and effects
10/13/2005US20050227939 Modulation of kallikrein 6 expression
10/13/2005US20050227938 Antisense modulation of TFAP2C expression
10/13/2005US20050227937 Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
10/13/2005US20050227936 RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
10/13/2005US20050227935 Controlling gene expression; mixture of small nucleic acids
1 ... 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 ... 870